• Lexaria Bioscience is dedicated to providing healthful alternatives to drug-substance inhalation by providing an edible technology that works as effectively as smoking or vaping at getting substances into the bloodstream
• The company’s DehydraTECH platform has been licensed to multiple companies in the cannabis and tobacco industries, and Canada’s recent nationwide legalization of cannabis edibles is expected to open even more of a market
• Gregg Smith, the founder of a New York-based “culture tech” venture investment firm, has joined Lexaria as a senior advisor to help define the company’s leadership strategies

Innovations in drug delivery are making the wellness product market safer and more effective in its niche as an alternative to costly pharmaceuticals or foreign remedies that lack governmental approval. Bio-delivery technology developer Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) is a world leader in edible drug science to combat the ills of substances that might otherwise be inhaled into the lungs.

Lexaria’s proprietary DehydraTECH™ drug delivery platform is patented to work with existing substances such as nicotine, cannabidiol (CBD) and other non-psychoactive and psychoactive cannabinoids to get orally ingestible versions of the substances into the bloodstream at speeds comparable to inhaled products, virtually eliminating a key reason people might risk sustained injury to their lungs to use those products.

“Wherever there are many victims from past injustices, there is a lot of anger and resentment that doesn’t go away easily,” CEO Chris Bunka told Forbes in discussing Lexaria’s aim to get nicotine users to move away from “life-threatening” smoking habits to satisfy their cravings (http://ibn.fm/oMc9G). “My father also died from lung cancer just last year, so I am no fan. … The fact that (DehydraTECH) is fast means that smokers might not be frustrated waiting for their nicotine experience to begin, the way they have been with traditional nicotine products such as gums and lozenges.”

Lexaria recently announced the appointment of Gregg Smith, the founder of a New York-based “culture tech” venture investment firm, as a senior advisor in helping define Lexaria’s leadership strategies.

“I am passionate about creating a smokeless future and recognize that the consumption methods of nicotine and cannabis will change,” Smith stated in the news release (http://ibn.fm/Srpvg). “Lexaria’s technology, DehydraTECH™, will completely disrupt and improve the consumption and delivery of oral nicotine, CBD and cannabis. Lexaria’s recognition of the recent FDA recognition of certain oral delivery forms of nicotine as ‘less harmful’ to human health than combustible smoking will be a driving force of changing consumer preferences.”

One strategy Lexaria has already been pursuing includes introducing DehydraTECH-licensed products to consumers through adult-format beverages, building on a relationship with Toronto-based Hill Street Beverage Company Inc. (TSX.V: BEER), a company renowned for its alcohol-free beers and wines.

“Our alcohol-free business continues to grow as more and more people turn away from alcohol and look for better alternatives. But we’re more than just the world’s most award-winning alcohol-free beverage company,” Hill Street’s website states (http://ibn.fm/JvQRy). “We’ve licensed a technology that allows us to take that award-winning adult-beverage portfolio and infuse it with cannabis… without any impact to the smell or the taste of the product.”

Canada legalized cannabis-infused edibles and beverages in October, and the first products are expected to begin hitting store shelves soon (http://ibn.fm/80XHA).

Market analysts at Deloitte predict the Canadian market for edibles and alternative cannabis products alone will be worth $2.7 billion a year, and that cannabis extract-based products including edibles will make up nearly 60 percent of the total at $1.6 billion (http://ibn.fm/1VkfJ).

Lexaria has already licensed its technology to multiple companies in North America in the cannabis and tobacco industries. The company operates a licensed in-house research laboratory and its IP portfolio includes 16 patents granted and over 60 patents pending worldwide.

For more information, visit the company’s website at www.LexariaBioscience.com

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://ibn.fm/LXRP

• To date, more than 16 million consumers around the world have joined; that number increases daily
• SRAX offers other powerful data-management tools

SRAX Inc. (NASDAQ: SRAX), a digital marketing and consumer data management technology company, has had more than 16 million consumers opt-in to its BIGtoken consumer-managed data platform since the product was released earlier this year. In addition, SRAX offers other powerful products designed to provide marketers and consumers with the tools to unlock the value of data.

During an interview at SNNLive at the Planet MicroCap Showcase 2019 in Las Vegas, SRAX CEO and co-founder Christopher Miglino was asked about the “secret sauce” to getting such a high response rate (http://ibn.fm/9L1mf). Miglino noted that the budget for the launch was $2 million, but the company started with a modest $20,000. “We spent twenty grand, and the thing went completely viral,” he said. “People started signing up all over the place. We were having around 700,000 invites a day going out through the platform, so people were inviting 700,000 a day to the platform… If you go to social media even today and you pull up Twitter and YouTube and Instagram, and type in BIGtoken, you’ll see thousands of posts, thousands of consumer engagements from people talking about how they love the platform.”

From that impressive start, BIGtoken has grown into an exclusive platform with more than 16 million opted-in consumers around the world. “BIGtoken is unique in the data set it has gathered, the way it rewards consumers who have opted in and the manner it provides access to that data to marketers,” Miglino observed. “Consumers are becoming much more aware of their own privacy. A few years ago, people didn’t care, but now all of a sudden, consumers are realizing that their data is worth a lot of money. We’re working very hard to create an environment where consumers own that data on their own, and when anybody wants to access that data, they are monetizing the issue.”

In addition to BIGtoken, SRAX provides other valuable technology tools that unlock data to reveal brands’ core consumers across marketing channels. Those tools include the following:

• SRAX Core allows users to integrate inventory and reporting from all vendors, channels and formats in one dashboard; build and save custom data segments in seconds; and gain deep insights into campaign optimization with a dedicated single point of contact;
• SRAX IR allows users to discover insights about their shareholders and market makers and their contributions to the company; manage and monitor ROI from investor relations firms; grow shareholder base with precise audience-building, targeting and delivery across programmatic and social channels; and save new contacts from investor events and provide them collateral within the platform;
• SRAX Auto allows users to use first-party data to ensure their brand is top of mind when known car buyers lease again; track and target test drivers and visitors to specific dealerships; link direct-mail programs to online ad targeting; and
• SRAX Shopper allows users to influence shoppers at the pivotal place and time with intent-based geotargeting; drive in-store foot traffic and purchases; and deliver personalized shopper-ad experiences.

Based in Los Angeles, SRAX is a digital-marketing and data-management technology company focused on building the largest and most valuable opted-in data set in the world. The company provides marketers, content owners and consumers with proprietary tools to unlock the value of that data. SRAX technology also unlocks data to reveal brands core consumers and their characteristics across marketing channels. SRAX delivers a digital competitive advantage for brands in the healthcare, CPG, automotive, sports and lifestyle verticals.

For more information, visit the company’s website at www.SRAX.com

NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://ibn.fm/SRAX

• SHRG operates in billion-dollar industry seeing consistent growth
• Company focusing on two subsidiaries designed to leverage opportunities
• Elepreneurs, Elevacity provide exclusive, powerful tools to help SHRG sales force experience happier, healthier, wealthier lives

In an industry that saw more than $35 billion in retail sales in 2018 and which has seen consistent growth over the past decade (http://ibn.fm/7X2qI), Sharing Services Global Corporation (OTCQB: SHRG) is working to reshape the growing space to meet the needs of a new generation of entrepreneurs working in a world of evolving technology and product offerings. SHRG, which owns, operates or controls an interest in an array of companies specializing in the direct-selling industry, has focused its efforts on its two relatively new, wholly owned subsidiaries – Elepreneurs LLC and Elevacity LLC – to make this happen.

In 2017 SHRG created Elepreneurs, a subsidiary designed for today’s entrepreneurs who are looking for greater flexibility with income opportunities along with a purpose and products that go beyond the traditional direct-selling approach. Through Elepreneurs, SHRG provides tools and products for its independent sales force, called Elepreneurs, to experience happier, healthier and wealthier lives.

Those tools include basic and advanced programs for both new and veteran members who want to make direct selling their primary careers. These powerful seminars, classes, boot camps and workshops were developed by Elepreneurs and are conducted by experienced entrepreneurs who are committed to providing participants with the mindset, skill set, knowledge, system, action plan, tools, awareness, motivation and confidence to build successful businesses. In addition, Elepreneurs offers diverse lanes of opportunity designed to provide a higher percentage of income generation and less attrition.

Elepreneurs is designed to be marketed in today’s world of social media, taking advantage of a widened consumer base that crosses industries and borders. SHRG’s unique relationship marketing breaks the traditional direct-selling mold, creating competitiveness and opportunities in small businesses across the company’s platform. This modern model reaches today’s market and consumers in an extremely cost-effective, personal and direct way.

SHRG’s subsidiary Elevacity is responsible for the manufacturing and distribution of the company’s products. SHRG offers superior, scientifically cultivated products that stimulate what the company calls happiness hormones – dopamine, oxytocin, serotonin and endorphins – or D.O.S.E.

The product line includes core offerings in the nutritional beverage category and unique skin-care products. Each product offered under the Elevacity brand is carefully formulated and designed to support a simple objective: elevating lives through products and services. As one of SHRG’s unique lanes of opportunity, Elevacity also offers a unique rewards program for its Elepreneurs.

Sharing Services is dedicated to maximizing shareholder value through the acquisition and development of innovative companies, products and technologies in the direct-selling industry. The Sharing Services combined platform leverages the capabilities and expertise of various companies that market and sell products direct to the consumer through independent contractors.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at  http://ibn.fm/SHRG

• Provider of revolutionary quality assurance software to the commercial 3D printing industry under the PrintRite3D® brand
• Estimated addressable market is $1.4 billion, projected to exceed $3.9 billion by 2023
• Currently, there are 23 Sigma Lab installations across 19 different users located around the globe
• Evaluations are underway with Tier-1 OEM clients for potential production-level software integration
• Experienced management team with deep industry experience, supplemented by an industry leading scientific advisory board
• Robust patent strategy established to protect intellectual property with seven patents granted, 18 patents pending, and four patent applications pre-publication

Sigma Labs Inc. (NASDAQ: SGLB) is the only provider of in-process quality-assurance software to the commercial 3D printing metal industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality, and avoid rejects. Sigma’s software is the singular solution that enables both real-time, in-process detection of quality control manufacturing irregularities for critical metal parts and then provides the operator the actionable information needed to adjust and mitigate the developing anomaly. Sigma Labs’ software represents a paradigm shift in the quality control process for the manufacture of 3D printed metal components. The nascent 3D metal printing industry is on the verge of radically altering the speed and technical complexity of manufactured parts. Further, it makes possible just-in-time availability of critical components – all at reduced cost, time, waste and weight. 3D printing, heralded as the fourth industrial revolution in manufacturing, will only truly surpass traditional techniques when the additive manufacturing industry moves from “post process” quality control to “in process” quality assurance.

For the industry to move from prototype manufacturing of critical components to economically viable commercial production, the 3D metal printing industry must find ways to dramatically increase production speed and quality yields, and to dramatically decrease the excessive cost of quality control. To achieve these prerequisites and move 3D metal printing into the mainstream, parts must be inspected and certified during the manufacturing process rather than after. Parts in the production process that are developing signs of quality control problems must be identified in real-time and alerts must be issued. The problem, along with the solution, must then be communicated to the machine operator to implement repairs.

Revolutionizing Additive Manufacturing

Sigma Labs, with its PrintRite3D® brand, has established a new benchmark in the development and commercialization of real-time computer aided inspection (“CAI”) solutions. Sigma Labs resolves the major roadblocks and costly quality control challenges that impede the 3D manufacture of precision metal parts. The company’s breakthrough computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance during production, uniquely allowing errors to be corrected in real-time.

Sigma Labs was founded in 2010 by a team of Los Alamos National Labs scientists and engineers to develop and commercially license advanced metallurgical products for the military ordinance, dental implants, and then for additive manufacturing (3D printing). After assessing 3D metal printing technology and the costly, inconsistent quality control issues, Sigma Labs concluded that the enormous potential of 3D metal printing could only scale up if in-process quality-assurance tools were developed to observe, manage and control the manufacturing complexities in such a manner that reliability and repeatability of very high precision quality metal parts could be achieved in the process. Sigma Labs’ patented and third-party validated software has achieved these objectives and now delivers the critical elements needed to unleash the promise of 3D metal printing.

Sigma Labs’ products and services are engineered, manufactured and qualified for use in the highly demanding and hyper precise production environments of the aerospace, defense, transportation, oil and gas, biomedical and other precision-dependent industries.

The Challenge

Additive metal manufacturing combines multiple processes and parts into one single 3D printed part. Due to variances in the additive manufacturing process, parts of consistent quality currently can’t be reliably produced in either large or small quantities without substantial postproduction inspection and rejection costs. Parts are inspected after production using CT scans and other means, so the manufacturer doesn’t know until the very end which of the finished parts meet design specifications. This means lost time, lost profits and inability to economically scale up production.

Innovative Approach

Sigma Labs solves this problem with its patented, in-process quality control technology that informs operators and engineers how to improve both the manufacturing process and quality by capturing meaningful data about inconsistencies in real-time. Sigma Labs is also partnering with OEMs, working toward the visionary introduction of revolutionary closed-loop control that will bypass the machine operator and automatically make in process corrections by reducing machine variations.

Sigma Labs’ next generation technology gives manufacturers the ability to make fast, virtual real-time adjustments so that each finished part is uniform and within critical specifications, thereby improving production quality, decreasing end-users’ risks and waste, and increasing profits and speed to market. Sigma Labs’ PrintRite3D® IPQA Software monitors and assesses the quality of each production part in the 3D additive manufacturing process – layer by layer, and in real-time. This has never been available until now.

Sigma Labs maintains a strong intellectual property portfolio consisting of trade secrets, process know-how and 34 patents either granted, pending or awaiting pre-publication around the globe. These patents encompass the fundamental technologies underlying Sigma Labs’ melt pool process control, data analytics, anomaly detection, signature identification, and future “closed-loop control” of 3D metal printing.

Market Opportunity

Providing advanced quality assurance software to the commercial 3D printing industry is currently a $1.4 billion addressable market expected to grow to $3.9 billion by 2023. Integrating Sigma Labs’ groundbreaking software helps arm the industry with a necessary catalyst to help enable and optimize the fourth industrial revolution in manufacturing.

Sigma Labs’ global client base includes 23 installations across 19 different users. Tier-1 OEM enterprises and end-users such as Siemens, Honeywell, Pratt & Whitney and others are currently evaluating PrintRite3D® for production lines.

Management Team

John Rice, CEO and chairman of the board of directors, has extensive experience as a CEO, lead negotiator, turnaround expert, business financier and crisis management executive/consultant. Prior to becoming chair and CEO of Sigma Labs, he was the CEO of a successful turn-around of a Coca-Cola Bottling Company. Rice has led a variety of companies in diverse business sectors and worked on a host of products and technologies including design and manufacture of high-end jet engine test equipment for the U.S. Airforce, chaff dispensers for F16s, software for modeling naval exercises, software for controlling warehouse distribution systems, medical radioisotopes, cancer detection, and cybersecurity. He is an honor’s graduate of Harvard College.

Darren Beckett, CTO, has over 20 years of experience in the semiconductor industry, including Intel Corporation, where he held various technical and managerial positions. His expertise in process engineering for advanced manufacturing technology includes statistical process control for fabrication of semiconductor devices.

CFO Frank D. Orzechowski also serves as treasurer, principal accounting officer, principal financial officer and corporate secretary. He has more than 30 years of distinguished financial and operational experience. Orzechowski began his career at Coopers & Lybrand in 1982, received his CPA certification in 1984, and received his Bachelor of Science in Business Administration with a major in accounting from Georgetown University in 1982.

Ronald Fisher, vice president of business development, is leading the commercialization of PrintRite3D® 5.0. Fisher is a mechanical engineer with hands-on experience in quality, manufacturing and product development. He has distinguished himself as a lead sales and marketing officer as well as a chief operating officer most recently before joining Sigma in technology startup that grew from market entry to successful exit by merger-acquisition.

For more information, visit the company’s website at www.SigmaLabsInc.com

NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://ibn.fm/SGLB

• InsuraGuest’s proprietary InsurTech software platform delivers a specialized guest protection policy to the vacation rental and hotel industries
• Multi-billion-dollar market opportunity is worldwide, with the European market more than double the size of the U.S. market
• Number of vacation rental users globally is expected to soar to 361 million, at a 38 percent CAGR over the next five years

Service-as-a-software (SaaS) company InsuraGuest Inc. delivers a specialized insurance policy that protects guests during their stay at hotels and vacation rental properties. Through its proprietary InsurTech software platform, InsuraGuest provides the first line of defense for clients, properties and guests in an industry that is expected to host more than 297 million total vacation rental users worldwide in 2019 (http://ibn.fm/c76VG).

The InsurTech software platform delivers guest protection, acting as the first line of defense against accidents and losses for both the guest and the hotel or vacation rental property. When vacation rentals and hotels purchase the InsuraGuest protection policy, the coverage extends to the property’s guests once they check in. InsuraGuest provides specific coverage for such things as accidental damage to rooms, lost or stolen items, medical expenses, death or dismemberment (http://ibn.fm/L8y6C).

InsuraGuest provides software can integrate with more than 70 hotel and vacation rental property management systems worldwide. InsuraGuest is being integrated with vacation rental property management systems like Hostfully Inc. out of San Francisco and their system Orbirental, which currently has approximately 2,500 properties onboarded.

InsuraGuest is also working to expand the scope of its InsurTech platform and insurance products to cover European Union member states and the United Kingdom, while expansion plans include entering Asia by mid-2020 (http://ibn.fm/BQ0fO). InsuraGuest has already signed a letter of intent with a licensed Master General Agent operating in these markets, which will allow the company to distribute its products and proprietary platform to the hotel and vacation rental markets in these regions.

According to InsuraGuest CEO Douglas Anderson, there were 2.8 billion hotel nights stayed in Europe, compared to approximately 1.1 billion in the U.S. in 2018. With distribution in Europe and the United States, InsuraGuest’s combined demographics will total 3.9 billion nights stayed, and will more than double its vacation rental opportunities.

For more information, visit the company’s website at www.InsuraGuest.com

NOTE TO INVESTORS: The latest news and updates relating to InsuraGuest are available in the company’s newsroom at http://ibn.fm/InsuraGuest

• Xalles Holdings is a company dedicated to building on blockchain and other technologies for solutions in the e-commerce, payments and financial reconciliation arenas
• Xalles’ most recent financials report showed the company’s fifth consecutive revenue-producing quarter and expectations for future revenue and asset growth
• The company remains bullish on cryptocurrencies such as bitcoin amid the market’s ups and downs, with recent worldwide rising trends underscoring crypto’s and Xalles’ potential

The potential benefits of riding out crypto volatility were again on display in late October as Bitcoin suddenly surged over $500 in just five minutes, joined in the ride by other top-20 coins that simultaneously posted gains, with some of them seeing double-digit price increases (http://ibn.fm/tmRye). A larger indication of alt-coins’ persistence emerged in trends developing at a national level in South America and Asia.

Fintech holding company Xalles Holdings Inc. (OTC: XALL) is an experienced payment systems and solutions builder that has become a dedicated believer in the cryptocurrency market, celebrating the upsides of crypto’s free trade system despite risks inherent in Bitcoin’s volatility such as when the alt-coin standard bearer experienced a series of significant drops after rallying to August highs.

Xalles’ primary aim is to offer payment solutions to consumers and to respond to more complex needs within large businesses and government entities, supporting and accelerating financial services technology development. Its revenue stream is built on a diversity of market segments inclusive of companies with business models that set up some manner of payment or financial transaction toll gate (http://ibn.fm/b6BMv).

Worldwide volumes for non-cash transactions were analyzed by Capgemini’s and BNP Paribas’ World Payments Report last year to establish a forecast, leading to a prediction they would climb from 538.6 billion transactions during 2017 to more than 1 trillion in 2022 at a CAGR of 14 percent, mostly driven by developing markets at an estimated CAGR of 30 percent in Asia thanks to China’s adoption of QR code-based payments (http://ibn.fm/6y0Dg).

China created some shockwaves October 24 when its president stated the government should lead the world in blockchain innovation, taking into account that China’s urban populations have been steadily advancing during recent years toward a goal of becoming the world’s first completely cashless society by 2020 (http://ibn.fm/oVOPy).

The country’s vice-chairman of the China Center for International Economic Exchanges (CCIEE) followed with reported comments that China will pioneer the first-ever blockchain-based central digital currency (http://ibn.fm/STgEo). Such alt-coin efforts enjoy some controversy because they rely on a central, government-controlled system similar to existing fiat operations but with centrally managed digital technology tools.

At the same time, Argentina generated news when Bitcoin usage rose there as disgruntled citizens traded 14.15 million Argentine pesos (ARS) amid government efforts to cap the number of U.S. dollars a person can purchase within a month at $200, a 98 percent plunge from the prior $10,000 allotment (http://ibn.fm/PdLI7).

The central bank decision was a bid to protect the national bank’s reserves at a time when the peso has experienced annual inflation of over 50 percent, but Bitcoin commentators argued a familiar free market theme with statements such as social media account Rhythm’s post, “It’s not your money if you need permission to use it,” underscoring the move by many of the country’s citizens to boost cryptocurrency accounts.

Xalles’ subsidiary Xalles Financial Services recently announced its partnership with ATN Trading to offer cryptocurrency trading. Xalles also anticipates multiple cryptocurrency asset portfolio acquisitions. The company’s subsidiaries also offer or will offer marketing capabilities, investment management, a proprietary software platform for post-payment audits, and non-profit fundraising platforms in addition to the company’s payment management operations.

Xalles’ ability to leverage blockchain and other technologies for e-commerce, payments, financial reconciliation, and payment auditing solutions positions it as a potential fintech market leader as cryptocurrencies continue to shore up their bases. The company recently reported its fifth consecutive revenue-producing quarter and expectations for future revenue growth, as well as asset value growth.

For more information, visit the company’s website at www.Xalles.com

NOTE TO INVESTORS: The latest news and updates relating to XALL are available in the company’s newsroom at http://ibn.fm/XALL

• POAI subsidiary Helomics announce sequencing of ovarian tumor cases from UPMC Magee collaboration, a critical step in strategic Cancer Quest 2020 initiative
• Data key to value in $48-billion precision-medicine industry
• Industry leaders such as POAI realize critical value in patient-specific, data-driven models

The field of drug development for cancer treatment involves costly and time-intensive research. As technology plays an ever-increasing role in driving medicine, researchers and clinicians are discovering the significant potential of patient-derived models in matching specific cancer types with their most effective treatments. These models, which harness the patients’ own cancer cells to best determine how to defeat them, have been shown to be “a valuable tool for the identification of new treatment targets” (http://ibn.fm/DBK3s). To prepare for this next major frontier of precision medicine, industry leaders realize the critical value in these patient-derived (PDx) models of cancer. While most competitors are just getting their feet wet in both developing these PDx models and generating data from them, Predictive Oncology Inc. (NASDAQ: POAI) has been swimming in the deep end for some time, boasting an immensely valuable historic database of drug response for patients from its own proprietary PDx tumor models.

In the precision-medicine industry, the value of any predictive model is directly related to the quality and quantity of data used to build it. The richer and more extensive a predictive model’s data set, the more accurate and generalizable the predictions become. This predictive value translates into tremendous dollar potential in the field of precision medicine, a $48 billion industry in 2018 (http://ibn.fm/F7n7L), and Predictive Oncology is well positioned in this regard. Through its partnership with UPMC Magee Women’s Hospital, POAI subsidiary Helomics has been able to analyze “the genomic and drug-response profiles of women with ovarian cancer to build AI-driven predictive model of response to therapy” (http://ibn.fm/YQKky). Recently, Helomics announced that it has begun sequencing the tumor cases from this collaboration, a critical step in its strategic Cancer Quest 2020 project (http://ibn.fm/F93kH) as POAI moves towards the goal of building out its extensive database of tumor drug-response data.

“These retrospective ovarian cancer cases were profiled [by] Helomics as early as 2010; hence, we have 10 years’ worth of drug-treatment data, survival and other outcome measures we are gathering from Magee’s clinical databases,” stated Helomics chief innovation officer Dr. Mark Collins. “We are now sequencing these cases, looking at both the tumor mutations (genome) as well as tumor-gene expression (transcriptome) to build a comprehensive multi-omic picture of the tumor. We are also using deep learning on histopathology images of the tumor tissue (tissue-omics) to add an additional dimension to this multi-omic profile. We believe the combination of the rich multi-omic profile of the tumor and clinical outcome data will allow us to build an AI-driven model of ovarian cancer capable of predicting the tumor drug response and patient outcome (prognosis).”

POAI’s platform, composed of over 150,000 patient tumors, harnesses the power of an individual patient’s tumor to help recommend the best treatment for that patient. This database, which houses evidence documenting actual drug responses of cancer patients’ individual tumors, uses artificial intelligence to create a valuable predictive tool for pharmaceutical companies and researchers.

Industry leaders believe that models utilizing patient-derived data powered by artificial intelligence will allow doctors to make more effective individualized treatment recommendations, changing the landscape of cancer treatment. The predictive models can be applied clinically for patients of today, and they can also be used in the development of new drugs by researchers to help cancer patients of tomorrow.

Predictive Oncology offers the potential for significant ROI as it focuses on improving patient outcomes, changing the status quo of cancer treatment.

For more information, visit the company’s website at www.Predictive-Oncology.com

NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://ibn.fm/POAI

• SHRG has generated $129 million in cumulative sales since its launch of own products; company revenue reached $35.4 million in Q1 2019, more than double sales from prior year
• ‘Blue Ocean Strategy’ is the unique and successful method for SHRG’s Elepreneur independent distributors to sell the company’s line of proprietary health and wellness products
• SHRG has global expansion plans to implement through 2019, according to John “JT” Thatch, CEO

Sharing Services Global Corporation (OTCQB: SHRG) has gained momentum in its record sales by employing its Blue Ocean Strategy, a unique and successful method of selling its proprietary product line through its Elepreneur independent distributors. Since the company’s own line of health and wellness products was introduced in December 2017, SHRG has reported cumulative sales of greater than $129 million. For Q1 2019, the three months ending July 31, Sharing Services reached revenues of $35.4 million, more than double that of the comparable period in 2018 (http://ibn.fm/YRX56).

The company’s deliberate approach stems from the book Blue Ocean Strategy by W. Chan Kim and Renée Mauborgne. The Blue Ocean Strategy is a systematic approach to selling that renders the competition irrelevant by creating and operating in an uncontested market space. The approach also calls for creating and capturing new demand, and strategy execution calls for exceeding expectations (http://ibn.fm/LswWJ).

The launch of SHRG’s proprietary line of health and wellness products in 2017 through its Elepreneurs LLC and Elevacity Global LLC subsidiaries marked a company milestone. The products all are based on the D.O.S.E. product formulation of four hormones designed to promote happiness and well-being (http://ibn.fm/c6477).

“Product sales for our incredible health and wellness products of Elevacity Global were strong from the beginning and have since dramatically and consistently increased,” SHRG CEO John “JT” Thatch stated in a news release (http://ibn.fm/xKj2j). The company has announced global expansion plans that it will continue to implement throughout 2019.

In a 10-K SEC filing, SHRG reported record sales of $85.9 million for its fiscal year ended April 30, 2019 (http://ibn.fm/PBGfz). This represents a nine-fold increase or $77.5 million jump from company revenues of $8.4 million the prior year.

“Our 2019 revenues are continued proof that our Blue Ocean Strategy is being implemented and accepted in the direct-selling marketplace,” Thatch added (http://ibn.fm/ihlxt). “We continue at a record-breaking pace as our dedicated and highly talented Elepreneurs continue to execute on the mission to change the direct selling industry with best-in-class products and services.”

Thatch noted that Elevacity Global has consistently increased its sales of health and wellness products. Since the product launch in late 2017, SHRG has supported expansion with several initiatives including establishing a new corporate headquarters to accommodate growth, bringing in experienced industry talent and pursuing global expansion plans.

In the 10-K filing, SHRG reported that since inception and for its FY ended April 30, 2019, some 97 percent of its consolidated net sales have been generated by the company’s health and wellness product line. Economies of scale and selective price increases helped SHRG raise its consolidated gross margin to 66.5 percent for its FY ended April 30, 2019, compared to 52.3 percent from the year earlier period.

SHRG is a Plano, Texas-based diversified holdings company that owns and operates companies engaged in direct selling through independent sales contractors as the sales force. The company also offers services such as energy, technology and insurance. Its divisions include Elevacity Global LLC and Elepreneur LLC.

For more information, visit the company’s website at www.SHRGInc.com

NOTE TO INVESTORS: The latest news and updates relating to SHRG are available in the company’s newsroom at http://ibn.fm/SHRG

• Wonderfilm Media is backed by four Hollywood producers with $1 billion worth of movie revenues between them
• Wonderfilm’s producing team is attending American Film Market to pre-sell intellectual properties for the company’s expanding slate of movies and television/streaming series and potentially solidify new projects
• With a $58 million total budget and 17 productions greenlit, Wonderfilm’s low-risk approach to content production results in predictable and consistent revenue streams

Wonderfilm Media Corporation (TSX.V: WNDR) (OTCQB: WDRFF), a publicly traded entertainment company, with offices in Los Angeles and Vancouver, has developed a risk-averse production process that provides forecastable and consistent revenues. This innovative approach assures that Wonderfilm productions are structured to start generating a return to the company as soon as the camera starts rolling.

Soaring demand for content from streaming providers is fueling industry growth with established media giants in an all-out sprint to dominate some very lucrative revenue streams, a Bloomberg article states (http://ibn.fm/k804y). One segment of this industry, the global video on demand market, was valued at $28.9 billion in 2017 and is expected to reach $89.3 billion by 2026 at a compound annual growth rate of 15.4 percent during the forecast period, according to a research report (http://ibn.fm/RzB15).

“The content creation opportunities in the market today are akin to a new gold rush. After 30 years in this business, I have never been more excited to be a movie and TV content producer,” Wonderfilm CEO Kirk Shaw, a prolific filmmaker with 230 films and seven TV shows to his credit, tweeted (http://ibn.fm/jldjq).

Wonderfilm currently has 17 films greenlit with combined budgets totaling $58 million. Wonderfilm production stars include: John Travolta, Nicolas Cage, Guy Pearce, Ryan Phillippe and Anne Heche, to name a few. Some of the company’s most notable greenlit projects include the horror film ‘Amityville 1974’, slated for theatrical release in October 2020, and the action film ‘Inside Game’ starring Tyrese Gibson, which will be released to theaters in fall 2020.

Wonderfilm has discussed plans to launch its own streaming channel (http://ibn.fm/Lx4jQ), but for now the company is focused on creating films for other distributors, both cinematic and online. Once the company secures a script and signs an A-list star, Wonderfilm pre-sells the film before shooting starts. Whether the project is sold to a streaming service or a cinematic distributor, this approach eliminates distribution risks. Not only does this secure much of the finance needed to make a film happen, it also ensures that the project will reach its audience (http://ibn.fm/Hy2mA).

Wonderfilm’s combined producer team of Kirk Shaw, Shaun Redick, Yvette Yates, Dan Grodnik, Bret Saxon and Jeff Bowler, is attending this year’s American Film Market (“AFM”) in Santa Monica, California – a first for the company and a perfect opportunity to implement the company’s business strategy, Shaw stated in a news release

“Getting ready for the American Film Market in Santa Monica is a busy time of year for all of us,” Shaw stated in a news release. “Shaun, Yvette and Dan have been preparing their AFM game plans for several months, while Bret and Jeff have been equally busy lining up strategic meetings with potential new production and distribution partners. It’s exciting for the Team, as well, since this is the first AFM the entire group is attending together to implement interconnected strategies that target different aspects of the film and television market – including pre-selling movies. AFM almost never disappoints, so in the weeks and months ahead, we expect to be able to announce new Wonderfilm movies and series achieved directly from participation in AFM 2019.”

For more information, visit the company’s website at www.Wonderfilm.com

NOTE TO INVESTORS: The latest news and updates relating to WDRFF are available in the company’s newsroom at http://ibn.fm/WDRFF

• Achieving considerable progress in the research and development of new products utilizing its innovative cannabinoid delivery systems
• In the process of introducing several cannabinoid consumer products based on the company’s internally developed high bioavailability infusion technologies
• Highly experienced management team with significant participation in the cannabis and hemp industries
• IP portfolio includes four patents on the company’s cannabinoid delivery technology systems

MCTC Holdings Inc. (OTC: MCTC) is an innovator in the field of cannabinoid nanoparticles and infusion technologies with several important cannabinoid patents filed and an active research and development program underway. The company was reorganized during June of 2019 and announced its intent to enter the cannabis sector and change its corporate identity to Cannabis Global Inc. The company is headquartered in Los Angeles, California.

With the hemp and cannabis industries rapidly expanding in terms of market size, acceptance and number of market participants, MCTC plans to concentrate its efforts on the middle portions of the hemp and cannabis value chain. The company is actively pursuing R&D programs and productization of advanced cannabinoid delivery systems, based on solid polymeric nanoparticles and fibers. These technologies hold the promise to revolutionize the science of cannabinoid bio-enhancement for use in foods, beverages, consumer products and in transdermal applications. Because of nanoparticles’ ability to be quickly absorbed into the bloodstream, nanotechnology has been utilized in the food and drug industry for some time and has the potential for tremendous growth in the cannabis industry (http://ibn.fm/so6ug).

Cutting-Edge Technology

MCTC is at the cutting-edge of the cannabis industry’s trends with its emphasis on polymeric nanotechnology. This is not to be confused with the more basic oil-in-water nano-emulsions currently marketed to the food and beverage industry. The company’s polymer-based particles offer significant loading of active ingredients and unmatched flexibility and customization, allowing for myriad combinations of cannabinoids with unique performance characteristics. MCTC believes polymeric nanotechnology particles will be a critical technology area for the cannabinoid formulation marketplace.

The company continues to build its R&D program, specifically researching the development of improving methods to make cannabinoids available to living systems. Instrumental in the research program is the development of novel polymeric nanoparticles and nanofibers. These have the potential to elevate the potential of cannabinoid products in the following ways (http://ibn.fm/K3LKz):

• Significantly improving bioavailability
• Allowing for ultra-high loading rates
• Enhancing customization of cannabinoid combinations
• Improved dosing precision
• Providing more control in release parameters

MCTC leadership understands the importance of developing intellectual property (IP) in the ever-evolving cannabis industry. A recent Forbes article described IP as “critical for creating true differentiation between companies and their product and service offerings” (http://ibn.fm/yPCj1). Recognizing the importance of IP, MCTC has been consistent in its application for patents to protect its innovative nanotechnology applications.

Patents

MCTC has now filed four patents on its cannabinoid delivery technology systems:

• The company first collaborated with Cannabis Nanosciences Inc. on technologies. This became the basis for its first patent filing on an innovative edible dissolvable film for cannabinoid ingestion.
• Its second patent filing for cannabinoid nanoparticles combined TPGS, a water-soluble form of vitamin E.
• Its third patent filing involved a unique 4th dimension, 3D printed cannabinoid delivery system for beverages.
• Its fourth patent, considered its most significant, broadly covers many aspects of nanoparticles and nano fibers comprising one or more cannabinoids disposed at least partially within a water-soluble medium.

Collaborations

MCTC collaborated with Marijuana Company Inc. (OTCQB: MCOA) subsidiary hempSmart Inc., under a hemp extract and CBD product supply agreement wherein hempSmart will utilize its extensive network of marketing partners to market MCTC’s powered drink mixes and other CBD edibles online. These products are designed for the dry beverage and edibles sector and will be supplied by MCTC. They incorporate the company’s patent-pending cannabinoid infusion technologies and will be trademarked as Hemp You Can Feel (TM) and Gummies You Can Feel (TM).

Leadership

MCTC CEO and chairman Arman Tabatabaei boasts 15 years of management and operations experience and is considered an expert at data collection and analysis relative to resource management, risk forecasting, and profit and loss management. He has acted as a consultant with Cannabis Strategic Ventures (OTCQB: NUGS) and played an instrumental role in improving operations at Sugarmade Inc. (OTCQB: SGMD) relative to the company’s hydroponic growth supplies initiatives.

MCTC founder and director Robert Hymers also brings a seasoned perspective, having had significant experiences in the cannabis industry and as a financial executive and consultant. He is the managing partner of Pinnacle Tax Services in Los Angeles and was previously CFO and director of Marijuana Company of America Inc. He is currently a member of the Strategic Advisory Board at Massroots Inc. and acts as a consultant to both Cannabis Strategic Ventures Inc. and Sugarmade Inc. Hymers’ background in tax accounting, auditing, SEC reporting, mergers and acquisitions, and corporate finance has immense value in his current position at MCTC Holdings.

For more information, visit the company’s website at www.CannabisGlobalInc.com

NOTE TO INVESTORS: The latest news and updates relating to MCTC are available in the company’s newsroom at http://ibn.fm/MCTC